Original Research
Published on 05 Feb 2026
Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still’s disease: a single-center retrospective study
in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
- 196 views